Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Regeneron Pharmaceuticals Inc. Stock

Price
Target price
€485.20

€485.20

1.000%
4.8
1.000%
€872.87
 
19:04 / Tradegate WKN: 881535 / Symbol: REGN / Name: Regeneron / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Wizard

Regeneron Pharmaceuticals Inc. Stock

The Regeneron Pharmaceuticals Inc. stock is trending slightly upwards today, with an increase of €4.80 (1.000%) compared to yesterday's price.
With 45 Buy predictions and 2 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 872 € shows a very positive potential of 79.72% compared to the current price of 485.2 € for Regeneron Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Regeneron Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Regeneron Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Regeneron Pharmaceuticals Inc. 1.000% -0.948% -4.455% -51.099% -28.977% -33.250% -0.805%
Incyte Corp. 0.310% 1.159% -1.378% 24.064% 8.886% 3.665% -2.943%
Exact Sciences -0.590% -0.616% 9.516% -29.220% -18.417% 28.650% -30.419%
Amgen Inc. -1.870% 5.384% -3.133% -19.622% -3.133% 3.629% 16.711%

Comments

Prediction Buy
Perf. (%) -3.32%
Target price 671.270
Change
Ends at 27.08.26

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Sanford C. Bernstein from $753.00 to $781.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Sanford C. Bernstein 
0
Report Share
27.08.25
Prediction Buy
Perf. (%) -4.64%
Target price 714.245
Change
Ends at 27.08.26

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Jefferies Financial Group Inc. from $813.00 to $831.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Jefferies Financial Group Inc. 
0
Report Share
27.08.25
Prediction Buy
Perf. (%) 1.93%
Target price 759.882
Change
Ends at 14.08.26

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $890.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Show more

Rothschild & Co Redburn 
0
Report Share
14.08.25
Show more
Not a member yet? Sign up for free!

News

Biotech Sector May Flip to Market Leader by Year-End: https://www.marketbeat.com/logos/articles/med_20250912080006_biotech-sector-could-be-flipping-to-an-outperforme.jpg
Biotech Sector May Flip to Market Leader by Year-End

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on the surface. Year-to-date, the iShares Nasdaq Biotechnology ETF (NASDAQ:

MarketBeat 
0 15.09.25
2 Beaten-Down Stocks to Buy on the Dip: https://g.foolcdn.com/editorial/images/831891/surgeons-in-an-operating-room.jpg
2 Beaten-Down Stocks to Buy on the Dip

Investors haven't been kind to Intuitive Surgical (NASDAQ: ISRG) and Regeneron Pharmaceuticals (NASDAQ: REGN) this year. Both healthcare leaders have encountered company-specific issues that have

TheMotleyFool 
0 07.09.25
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts: https://g.foolcdn.com/editorial/images/829101/pharmacist-talking-to-patient.jpg
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the

TheMotleyFool 
0 24.08.25